A Comparative Study on the Effect of Vitamin B6 and Cabergoline in Preventing Risperidone-Induced Hyperprolactinemia in Adolescent Female Wistar Rats

Abstract Context: Hyperprolactinemia is a common side effect of antipsychotic medications, including risperidone, resulting from the blockade of dopamine receptors in the hypothalamus. This condition can lead to various complications, emphasizing the need for effective preventive measures. Objective: This study aimed to investigate the efficacy of Vitamin B6 supplementation and compare it with Cabergoline administration as a preventive measure for risperidone-induced hyperprolactinemia. Design, Setting, Patients, and Intervention: An experimental study was conducted using inbred adolescent female Wistar rats. The rats were divided into four groups: Control, Standard (risperidone only), Test 1 (risperidone + Vitamin B6), and Test 2 (risperidone + Cabergoline). The interventions were administered orally for 14 days. Outcome Measures: The primary outcome measure was the serum prolactin level, assessed using the Elisa method and the Elabscience Rat PRL Elisa Kit. Results: The results showed that Vitamin B6 and Cabergoline significantly reduced serum prolactin levels compared to the standard group (p < 0.05). However, Vitamin B6 supplementation exhibited a slightly greater reduction (60%) than Cabergoline (75%). Conclusion: Vitamin B6 supplementation may be an effective preventive measure for risperidone-induced hyperprolactinemia. It demonstrated comparable efficacy to Cabergoline but with the advantage of being more affordable and having fewer side effects. Further research is warranted to validate these findings in human populations and explore the feasibility of Vitamin B6 as a prophylactic measure for antipsychotic-induced hyperprolactinemia.